Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R. Crump M, et al. Among authors: iglesias j. Cancer. 2004 Oct 15;101(8):1835-42. doi: 10.1002/cncr.20587. Cancer. 2004. PMID: 15386331 Free article. Clinical Trial.
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R, Crump M. Baetz T, et al. Among authors: iglesias j. Ann Oncol. 2003 Dec;14(12):1762-7. doi: 10.1093/annonc/mdg496. Ann Oncol. 2003. PMID: 14630682 Free article. Clinical Trial.
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D; For ANZGOG and HCRN Collaborative Groups. Lindemann K, et al. Among authors: iglesias jl. Cancer Chemother Pharmacol. 2019 Jan;83(1):97-105. doi: 10.1007/s00280-018-3706-5. Epub 2018 Oct 27. Cancer Chemother Pharmacol. 2019. PMID: 30368585 Clinical Trial.
847 results